50% off all subscriptions! ... left. Order NowOrder Now

Atara Biotherapeutics Stock Forecast NASDAQ:ATRA

$17.57 (-3.20%)

Volume: 414k

Closed: Nov 26, 2021

Hollow Logo Score: 2.116

Atara Biotherapeutics Stock Forecast

$17.57 (-3.20%)

Volume: 414k

Closed: Nov 26, 2021

Score Hollow Logo 2.116
Which way will ATRA go? Request
Stop-loss: $16.81 (-4.31%)
Key Stats
Beta 1.12
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 25 - 75 ] RSI14 is 43 and the stock is currently not being overbought or oversold

Red day on Friday for Atara Biotherapeutics
(Updated on Nov 26, 2021)

Buy or Hold candidate since 2021-11-01 Gain 6.42%

The Atara Biotherapeutics stock price fell by -3.20% on the last day (Friday, 26th Nov 2021) from $18.15 to $17.57. During the day the stock fluctuated 6.11% from a day low at $17.03 to a day high of $18.07. The price has risen in 6 of the last 10 days and is up by 0.17% over the past 2 weeks. Volume has increased on the last day by 75 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 414 thousand shares were bought and sold for approximately $7.28 million.

The stock lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 12.56% during the next 3 months and, with a 90% probability hold a price between $17.69 and $23.00 at the end of this 3-month period.

Signals & Forecast

A sell signal was issued from a pivot top point on Thursday, November 04, 2021, and so far it has fallen -11.66%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume rose on falling prices yesterday. This may be an early warning and the stock should be followed more closely. Some positive signals were issued as well, and these may have some influence on the near short-term development. The Atara Biotherapeutics stock holds a sell signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock. On further gains, the stock will meet resistance from the short-term moving average at approximately $17.99. On a fall, the stock will find some support from the long-term average at approximately $16.90. A break-up through the short-term average will send a buy signal, whereas a breakdown through the long-term average will send a sell signal.

Support, Risk & Stop-loss

On the downside, the stock finds support just below today's level from accumulated volume at $15.66 and $14.98. There is natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Atara Biotherapeutics finds support just below today's level at $15.66. If this is broken, then the next support from accumulated volume will be at $14.98 and $14.70.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $1.04 between high and low, or 6.11%. For the last week, the stock has had a daily average volatility of 5.10%.

Our recommended stop-loss: $16.81 (-4.31%) (This stock has medium daily movements and this gives medium risk. There is a sell signal from a pivot top found 15 days ago.)

Is Atara Biotherapeutics stock A Buy?

Several of the signals/indicators are negative, and we believe that this will affect on the development for the next days and maybe possible weeks. However, over time, we think that today's level holds a possible buying opportunity and that the price will be higher during or at the end of this 3-month period.

Current score: 2.116

Predicted Opening Price for Atara Biotherapeutics of Monday, November 29, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price November 29, 2021 Current price
$17.56 $17.57 (Overvalued)
Buy Candidate Unchanged

Remember To Visit Our YouTube Channel

Analyst Ratings

On Oct 13, 2021 "Mizuho" gave "$41.00" rating for ATRA. The price target was changed from $15.95 to 11.3%.

Volatility and Risk
Daily Average Volatility: 5.10 %
Overall Risk: Very High High Medium Low Very Low
5.10 %
Daily Average Volatility
Overall Risk

Very High
Very Low

Support & Resistance

Resistance: $17.62
Price: $17.57
Support: $15.66

ATRA Insider Trading Show all Trades



Last 100 transactions
Buy: 1 180 516 | Sell: 241 827 (Shares)
Date Action Amount Person Type
Nov 16, 2021 Sell 8 402 Touchon Pascal Common Stock
Nov 16, 2021 Sell 3 332 Newell Joe Common Stock
Nov 16, 2021 Sell 2 199 Dupont Jakob Common Stock
Nov 16, 2021 Sell 3 655 Koppikar Utpal Common Stock
Nov 16, 2021 Sell 2 124 Murugan Amar Common Stock
Show all Insider Trades


Last 100 transactions
Buy: 1 180 516 | Sell: 241 827 (Shares)

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 18.60 5.85 %
18.20 3.58 %
17.95 2.19 %
Current price: 17.57
Support 17.16 -2.34 %
16.91 -3.73 %
16.52 -6.00 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 17.80 1.31 %
17.64 0.40 %
17.62 0.28 %
Current price 17.57
Support 15.66 -10.87%
14.98 -14.74%
14.70 -16.33%

Click to get the best stock tips daily for free!

About Atara Biotherapeutics

Atara Biotherapeutics Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for patients with severe and life-threatening diseases. Its products under development include EBV-CTL, which is Phase II clinical trials for the treatment of malignancies associated with Epstein Barr Virus (EBV), including EBV-associated post-transplant lymphoproliferative disorders; CMV-CTL that is in Phase II clinical trials for the treatme... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE